Abstract:As a part of the rapidly advancing organ-on-chip field of research, tumor-on-chip technology (TOC) has emerged as a promising co-culture system to mimic the mechanical and biochemical properties of the tumor microenvironment. This includes factors such as oxygen and nutrient gradients, extracellular matrix stiffness, and cell-cell interactions. Depending on the complexity of system, TOCs are miniature tumor models in a microfluidic chip allowing researchers to gain a better understanding and controlled cancer environment to effectively test potential drug treatments and study immune cell co-cultures. Champions'TumorGraft3D (CTG3D), established from patient-derived xenografts, is the essential component used to recapitulate tumor microenvironment in the TOC platform which provides an even more powerful tool to gain more insight on the efficacy of various therapeutics. Here, we demonstrate the value in combining microfluidic devices with well characterized CTG3D models at Champions Oncology focused on indications including colorectal, breast, gastric and lung cancer. In brief, we optimized cell seeding conditions in both top (seeded with CTG3Ds) and bottom (seeded with endothelial cells) channels to develop TOCs interfacing epithelial-endothelial cells. These established systems may be applied as a baseline for introducing additional cell types such as autologous tumor-infiltrating lymphocytes (TILs) and studying their effect in the presence and absence of additional treatments. With an initial focus on colorectal cancer, we successfully developed TOC epithelial-endothelial interface using CTG3Ds originated from patients with various clinical backgrounds. We measured the permeability as an initial read-out to prove that although tumor cells do not inherently form a tight barrier, they can still form a non-leaky barrier with distinct organoid-like structures. Next, we extended our study to additional indications featuring unique characteristics and proved the feasibility of applying TOCs as a preclinical tool regardless of the tissue-of-origin. In all cases, the endothelial cells formed mature microvascular structures and to confirm the consistency of formed epithelial-endothelial interface among the replicates of each experimental group, we did Luminex studies to prove high consistency in secreted proteins. Regarding the functionality of TOCs, we investigated the effect of relevant test agents to each indication and showed that that the combination of DRAQ7 dye and high-content imaging may be a reliable read-out to detect the response and viability of cancer cells pre- and post-treatment. In summary, our established tumor-on-chip system proves to be a robust and powerful tool for studying the effect of microenvironmental factors in drug testing and immune cells in cancer progression. Citation Format: Samaneh Kamali, Mara Gilardi, Brandon Walling, Abhay Andar, Karin Abarca-Heidemann, Maria Mancini. Tumor-on-chip co-culture system: A comprehensive tool in personalized medicine to study cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4285.

Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions.

Evaluation of cancer immunotherapy using mini-tumor chips

Ex Vivo Evaluation of Combination Immunotherapy Using Tumor-Microenvironment-on-Chip.

Ex vivo quantification of anti-tumor T-cell activity upon anti-PD-1 treatment in patient-derived lung tumor-on-chip

Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment

Profiling of Immune-Cancer Interactions at the Single-Cell Level Using a Microfluidic Well Array.

Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies

Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model

Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays

Abstract 6771: Tumor-microenvironment-on-chip: an ex vivo drug screening platform enabling real-time observation of regional tumor responses during drug development and clinical treatments

Recapitulating the Cancer-Immunity Cycle on a Chip

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells

Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors

Genetic and Phenotypic Profiling of Single Living Circulating Tumor Cells from Patients with Microfluidics

Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening

Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip

Imaging‐based Efficacy Evaluation of Cancer Immunotherapy in Engineered Tumor Platforms and Tumor Organoids

Abstract 4285: Tumor-on-chip co-culture system: A comprehensive tool in personalized medicine to study cancer progression

Acoustofluidic assembly of primary tumor-derived organotypic cell clusters for rapid evaluation of cancer immunotherapy

Combining Scalable Organ Chip Platform with Deep Learning-Based Imaging Analysis for Cancer Therapeutic Screening